MBX Biosciences, Inc. — Form SCHEDULE 13D/A
Filed August 10, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC jointly filed Amendment No. 3 to Schedule 13D on August 10, 2026, regarding their holdings of MBX Biosciences common stock (par value $0.0001/share). The filing is a procedural joint filing agreement; specific share counts, ownership percentages, and details of what changed are not disclosed in this exhibit.
Why this rating
Routine procedural amendment to existing 13D filing. No material facts disclosed: share count, ownership %, or substantive changes unknown from this exhibit alone.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.